Ekso Bionics Holdings, Inc. (NASDAQ: EKSO)

Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products that augment human strength, endurance, and mobility. The company operates primarily in the healthcare industry, focusing on individuals with physical disabilities or impairments. Its technology is used for both physical rehabilitation and mobility, catering to a market that includes clinical settings and individual users. Founded in 2005, Ekso Bionics has established itself as a pioneer in the field of wearable robotic exoskeletons, aiming to improve mobility and quality of life for its users.

The company generates revenue through the sale of its exoskeleton products and related services. Its primary products include the EksoNR, Ekso Indego Therapy, and Ekso Indego Personal devices, which are designed for rehabilitation and mobility purposes. Additionally, Ekso Bionics offers services such as extended warranty and premium service options under its EksoCare program, device servicing and repair, and training programs. The customer base for these products and services includes rehabilitation facilities, individual users, and healthcare providers.

• Enterprise Health: This segment focuses on the sale of products and services related to neurorehabilitation in clinical settings. Key products in this segment include the EksoNR and Ekso Indego Therapy devices, which are used in inpatient rehabilitation facilities, long-term acute care hospitals, skilled nursing facilities, and outpatient rehabilitation clinics. The segment also includes the EVO product, which is marketed to commercial and industrial companies to solve ergonomic challenges for workers. The Enterprise Health market is the primary revenue driver for Ekso Bionics, with a focus on educating clinical and executive stakeholders on the economic and clinical value of its robotic exoskeleton portfolio.

• Personal Health: This segment caters to individual users with mobility impairments, primarily those with spinal cord injuries (SCI). The key product in this segment is the Ekso Indego Personal device, which enables users to walk independently in community and home settings. The Personal Health market is served through Durable Medical Equipment suppliers (DMEs) and other channel partners, with reimbursement programs involving worker's compensation, VA, or Medicare. The segment also includes the Ekso Nomad product, which is currently in limited volumes for use in a non-Company-sponsored single clinical study and expected to begin general commercialization in late 2026.

Ekso Bionics operates in a competitive industry characterized by intense competition and rapid technological change. The company faces competition from products that target lower extremity gait therapy, ambulation, and rehabilitation in various clinical settings. Key competitors include traditional non-robotic therapy methods, mechanical or robotic therapy devices, and other exoskeleton manufacturers. Ekso Bionics differentiates itself through its clinical evidence supporting better outcomes for patients and the ability to help avoid or prevent fatigue and injuries to physical therapists. The company's competitive advantages include its extensive intellectual property portfolio, customer-focused approach to new product development, and a strong focus on research and development to enhance functionality, improve reliability, and reduce costs.

The customer base for Ekso Bionics includes a range of rehabilitation facilities, individual users, and healthcare providers. Specific customers mentioned in the filing include the U.S. Department of Veterans Affairs (VA), which has an active program to provide products like Ekso Indego Personal to U.S. veterans with SCI. The company also works with Durable Medical Equipment suppliers (DMEs) and other channel partners to serve the Personal Health market. Additionally, Ekso Bionics collaborates with integrated delivery networks (IDNs) and other healthcare providers to expand its market reach and provide comprehensive solutions for rehabilitation and mobility.